Trial intelligence / Profile preview

Phase II randomized study of radiotherapy and hormone therapy with or without docetaxel in high-risk localized prostate cancer

2008-003554-14Phase 2Active

Sponsor: GETTUM
Start: Aug 2008
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 2, randomised, open-label trial of docetaxel in prostate cancer (PCa) (2 arms), sponsored by GETTUM. Primary endpoint: Biochemical relapse-free survival at 5 years. Started Aug 2008; status: active.

Drugs

docetaxel

Conditions

prostate cancer (PCa)

Beyond the preview

Go deeper on 2008-003554-14.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-003554-14.